新型冠状病毒感染肺部影像学病灶延迟吸收相关因素分析

doi:10.19983/j.issn.2096-8493.20240354

摘要/Abstract

摘要： 目的: 分析新型冠状病毒感染肺部影像学病灶延迟吸收相关因素。方法: 根据影像学显示渗出浸润影完全吸收超过4周或吸收50%超过2周者纳入延迟吸收组,在4周内完全吸收或2周内吸收超50%的患者纳入对照组。收集临床资料并采用统计学软件分析并比较各危险因素。结果: 单因素分析全体患者延迟吸收组年龄明显高于对照组,以及延迟吸收组住院期间淋巴细胞谷值、核酸转阴时间、临床分型与对照组比较差异有统计学意义（P<0.05）;亚组分析时,在中型患者组延迟吸收组患者住院期间淋巴细胞谷值显著低于对照组,重型病例组中延迟吸收组淋巴细胞谷值、合并慢性肺病与对照组比较差异有统计学意义（P<0.05）;logistic多因素回归分析显示危险因素有核酸转阴时间、淋巴细胞谷值、临床分型。结论: 延迟吸收性新型冠状病毒感染在重型、危重型患者中多见;核酸转阴时间、淋巴细胞谷值、临床分型是该类肺炎的危险因素,因此,临床诊疗过程中及早抗病毒促进核酸转阴、预防病情进展为重或危重型、增强免疫力提升淋巴细胞可能改善新型冠状病毒感染患者预后,减少延迟吸收的发生。

关键词: 新型冠状病毒感染, 延迟吸收, 因素分析, 统计学

翟鹏勇, 张潇雅, 马文途, 苏凝, 赵素霞. 新型冠状病毒感染肺部影像学病灶延迟吸收相关因素分析[J]. 结核与肺部疾病杂志, 2024, 5(S): 30-34. doi: 10.19983/j.issn.2096-8493.20240354

参考文献

[1] Zhou P, Yang X L, Wang X G, et al.Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin.Nature, 2020, 579(7798): 270-273.
[2] Zhu N, Zhang D, Wang W, et al.A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med, 2020 , 382(8):727-733. doi: 10.1056/NEJMoa2001017.
[3] Garg M, Maralakunte M, Garg S, et al.The conundrum of‘LongCOVID-19’: a narrative review.Int J Gen Med, 2021, 14: 2491-2506.doi: 10.2147/ijgm.S316708.
[4] Cabrera martimbianco AL, Pacheco RL, Bagattini ÂM, et al.Frequency, signs and symptoms, and criteria adopted for long COVID-19: a systematic review.Int J Clin Pract, 2021, 75( 10): e14357.doi: 10.1111/ijcp.14357.
[5] Yan Z, Yang M, Lai CL.Long COVID-19 syndrome: a comprehensive review of its effect on various organ systems and recommendation on rehabilitation plans . Biomedicines, 2021, 9( 8): 966.doi: 10.3390/biomedicines9080966.
[6] Wang Y, Dong C, Hu Y, et al.Temporal changes of CT findings in 90 patients with COVID-19 pneumonia: a longitudinal study . Radiology, 2020, 296( 2): e55-e64. doi: 10.1148/radiol.2020200843.
[7] Garg M, Gupta P, Maralakunte M, et al.Diagnostic accuracy of CT and radiographic findings for novel coronavirus 2019 pneumonia: systematic review and meta-analysis.Clin Imaging, 2021, 72: 75-82. doi: 10.1016/j.clinimag.2020.11.021.
[8] Mo X, Jian W, Su Z, et al.Abnormal pulmonary function in COVID-19 patients at time of hospital discharge.Eur Respir J, 2020, 55( 6): 2001217. doi: 10.1183/13993003.01217-2020.
[9] Rome L, Murali G, Lippmann M. Nonresolving pneumonia and mimics of pneumonia. Med Clin North Am.2001, 85(6):1511-30, xi. doi: 10.1016/s0025-7125(05)70393-x.
[10] Rodrigues S, de Sá KS, Ishimoto AY, et al. Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. J . Exp Med, 2021, 218:e20201707. doi: 10.1084/jem.20201707.
[11] Del Valle DM, Kim-Schulze S, Huang HH, et al.An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med, 2020, 26:1636-1643. doi: 10.1038/s41591-020-1051-9.
[12] Ma L, Sahu SK, Cano M, et al. Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection. Sci Immunol, 2021 , 6(59):eabh2259. doi: 10.1126/sciimmunol.abh2259.
[13] Zhang Q, Bastard P, Liu Z, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science, 2020 , 370(6515):eabd4570. doi: 10.1126/science.abd4570.
[14] Wang EY, Mao T, Klein J, et al.Yale IMPACT Team Diverse functional autoantibodies in patients with COVID-19. Nature, 2021, 595:283-288. doi: 10.1038/s41586-021-03631-y.
[15] Gousseff M, Penot P, Gallay L, et al.Clinical recurrences of COVID-19 symptoms after recovery: Viral relapse, reinfection or inflammatory rebound? J Infect, 2020 , 81(5):816-846. doi: 10.1016/j.jinf.2020.06.073.
[16] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with2019 novel coronavirus in Wuhan, China. Lancet, 2020, 395(10223): 497-506.doi: 10.1016/S0140-6736(20)30183-5.
[17] Zhang X, Tan Y, Ling Y, et al. Viral and host factors related to the clinical outcome of COVID-19. Nature, 2020, 583(7816):437-440. doi: 10.1038/s41586-020-2355-0.
[18] 高凤萍, 黄敏梅, 高小亮, 2021年新型冠状病毒肺炎临床研究最新进展.中华医院感染学杂志, 2021, 31(19):2910-2914.doi:10.11816/cn.ni.2021-210351.
[19] Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med, 2020, 8(4): 420-422. doi: 10.1016/S2213-2600(20)30076-X.
[20] Zhou Y, Fu B, Zheng X, et al.Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients. Natl Sci Rev, 2020 , 7(6):998-1002. doi: 10.1093/nsr/nwaa041.
[21] Li H, Liu L, Zhang D, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet, 2020, 395(10235): 1517-1520. doi: 10.1016/S0140-6736(20)30920-X.
[22] Siemieniuk RA, Bartoszko JJ, Ge L, et al.Drug treatments for COVID-19: living systematic review and network meta-analysis[Update 2]. BMJ, 2020, 370:m2980. doi: 10.1136/bmj.m2980.
[23] Gong Y, Guan L, Jin Z, et al.Effects of methylprednisolone use on viral genomic nucleic acid negative conversion and CT imaging lesion absorption in COVID-19 patients under 50 years old. J Med Virol, 2020 , 92(11):2551-2555. doi: 10.1002/jmv.26052.